Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Trial Profile

Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Methotrexate (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top